Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation?
Tze‐Fan Chao(National Yang Ming Chiao Tung University), Shih‐Ann Chen(Heart Rhythm Society), Gregory Y.H. Lip(University of Liverpool), Yu‐Feng Hu(China Agricultural University), Li‐Wei Lo(National Yang Ming Chiao Tung University), Yenn‐Jiang Lin(National Yang Ming Chiao Tung University), Tzeng‐Ji Chen(Taipei Veterans General Hospital), Chia‐Jen Liu(National Yang Ming Chiao Tung University), Shih‐Lin Chang(National Yang Ming Chiao Tung University), Kang-Ling Wang(National Yang Ming Chiao Tung University), Ta‐Chuan Tuan(National Yang Ming Chiao Tung University)
Cited by 258
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Antithrombotic Therapy for Atrial Fibrillation
|CHEST Journal|2012|919